Progenics Pharmaceuticals, Inc. [NASDAQ:PGNX]: Analyst Rating and Earnings

Equities traders oftentimes stay updated on what leading stock market analysts say about a potential stock purchase. When it comes to Progenics Pharmaceuticals, Inc. [PGNX], the most recently available average analyst rating is from the quarter that ends in December. On average, stock market experts give PGNX an Buy rating. Its stock price has been found in the range of 3.62 to 9.42. This is compared to its latest closing price of $4.53.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Progenics Pharmaceuticals, Inc. [PGNX] is sitting at 1.50. This is compared to 1 month ago, when its average rating was 1.60.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Wed 8 May (In 47 Days).

Fundamental Analysis of Progenics Pharmaceuticals, Inc. [PGNX]

Now let’s turn to look at profitability: with a current Operating Margin for Progenics Pharmaceuticals, Inc. [PGNX] sitting at -313.38.

This company’s Return on Total Capital is -37.53, and its Return on Invested Capital has reached -57.20%. Its Return on Equity is -81.20, and its Return on Assets is -42.61. These metrics suggest that this Progenics Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Progenics Pharmaceuticals, Inc. [PGNX] has generated a Total Debt to Total Equity ratio of 44.12. Similarly, its Total Debt to Total Capital is 30.62, while its Total Debt to Total Assets stands at 26.31. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 38.76, and its Long-Term Debt to Total Capital is 26.90. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -5.91. The Enterprise Value to Sales for this firm is now 17.96, and its Total Debt to Enterprise Value stands at 0.19. Progenics Pharmaceuticals, Inc. [PGNX] has a Price to Book Ratio of 3.51.

Shifting the focus to workforce efficiency, Progenics Pharmaceuticals, Inc. [PGNX] earns $197,747 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 4.02 and its Total Asset Turnover is 0.10. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 6.15 and its Current Ratio is 6.15. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Progenics Pharmaceuticals, Inc. [PGNX] has 84.55M shares outstanding, amounting to a total market cap of $388.93M. Its stock price has been found in the range of 3.62 to 9.42. At its current price, it has moved by -51.15% from its 52-week high, and it has moved 27.07% from its 52-week low.

This stock’s Beta value is currently 2.43, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 55.48. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Progenics Pharmaceuticals, Inc. [PGNX] a Reliable Buy?

Progenics Pharmaceuticals, Inc. [PGNX] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.